Rejuvenate Bio
Rejuvenate Bio is a biotechnology company focused on developing gene therapies to treat age-related diseases in humans and dogs. Their mission is to create treatments that address chronic, age-related conditions, leveraging innovative gene therapy approaches to extend healthspan and lifespan. They collaborate with academic institutions and industry partners to advance their scientific research and clinical programs.
Industries
Nr. of Employees
small (1-50)
Rejuvenate Bio
San Diego, California, United States, North America
Products
RJB-0402 (liver-directed gene therapy expressing FGF21)
A liver-directed gene therapy candidate designed to express the FGF21 protein to address metabolic and age-related disease biology; developed as a single-dose therapeutic intended to provide durable systemic exposure to the therapeutic protein.
RJB-0402 (liver-directed gene therapy expressing FGF21)
A liver-directed gene therapy candidate designed to express the FGF21 protein to address metabolic and age-related disease biology; developed as a single-dose therapeutic intended to provide durable systemic exposure to the therapeutic protein.
Services
Canine gene therapy clinical trial for Mitral Valve Disease (MVD)
On-site veterinary clinical trial recruiting dogs with staged valvular heart disease to evaluate safety and efficacy of a cardio-protective gene therapy; includes enrollment, staging, and outcome assessment performed at a veterinary medical center.
Partnership and commercialization collaboration for veterinary gene therapies
Collaborative development and commercialization arrangements with animal health companies to support product development, regulatory filing, and market introduction of veterinary gene therapy products.
Canine gene therapy clinical trial for Mitral Valve Disease (MVD)
On-site veterinary clinical trial recruiting dogs with staged valvular heart disease to evaluate safety and efficacy of a cardio-protective gene therapy; includes enrollment, staging, and outcome assessment performed at a veterinary medical center.
Partnership and commercialization collaboration for veterinary gene therapies
Collaborative development and commercialization arrangements with animal health companies to support product development, regulatory filing, and market introduction of veterinary gene therapy products.
Expertise Areas
- Gene therapy development
- Preclinical translational research
- Veterinary clinical trials and animal health development
- Aging biology and cellular reprogramming
Key Technologies
- Gene therapy
- AAV liver-tropic vector delivery
- Secreted protein expression via gene delivery
- Partial cellular reprogramming via transgene expression